Vertex Pharmaceuticals (VRTX) Short term Debt (2009 - 2016)

Vertex Pharmaceuticals (VRTX) has reported Short term Debt for 6 consecutive years, with $300.0 million the latest figure, recorded in Q4 2016.

• In Q4 2016, Short term Debt rose 320.78% year-over-year to $300.0 million; the TTM figure through Dec 2016 stood at $300.0 million (up 320.78% YoY), while the FY2016 annual figure was $300.0 million, up 320.78% from the prior year.
• Short term Debt came in at $300.0 million for Q4 2016 at Vertex Pharmaceuticals, up from $297.8 million in the prior quarter.
• The five-year high for Short term Debt was $300.0 million in Q4 2016, with the low at $14.2 million in Q4 2014.
• Average Short term Debt over 3 years is $140.3 million, with a median of $108.8 million recorded in 2015.
• The largest YoY upside for Short term Debt was 416.82% in 2016 against a maximum downside of 320.78% in 2016.
• Year by year, Short term Debt stood at $14.2 million in 2014, then soared by 401.87% to $71.3 million in 2015, then jumped by 320.78% to $300.0 million in 2016.
• According to Business Quant data, Short term Debt over the past three periods registered $300.0 million, $297.8 million, and $221.6 million for Q4 2016, Q3 2016, and Q2 2016 respectively.